Cresco Labs Inc.

CNSX:CL Stock Report

Market Cap: CA$572.2m

Cresco Labs Management

Management criteria checks 2/4

Cresco Labs' CEO is Charlie Bachtell, appointed in Feb 2015, has a tenure of 11.33 years. total yearly compensation is $1.42M, comprised of 34.6% salary and 65.4% bonuses, including company stock and options. directly owns 0.6% of the company’s shares, worth CA$3.43M. The average tenure of the management team and the board of directors is 6.7 years and 9.5 years respectively.

Key information

Charlie Bachtell

Chief executive officer

US$1.4m

Total compensation

CEO salary percentage34.64%
CEO tenure11.3yrs
CEO ownership0.6%
Management average tenure6.7yrs
Board average tenure9.5yrs

Recent management updates

Recent updates

Narrative Update May 05

CL: Lower P/E Expectations Will Support A More Upside Skewed Profile

Analysts now see Cresco Labs trading closer to CA$2.25 rather than CA$2.50, reflecting updated views on fair value, growth assumptions, profitability, discount rate and future P/E expectations. Analyst Commentary Bearish analysts have adjusted their view on Cresco Labs, with a lower price target of CA$2.25 compared with the earlier CA$2.50 level.
Narrative Update Apr 20

CL: Discount-Adjusted Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have trimmed their CA$ price target on Cresco Labs from CA$2.50 to CA$2.25, reflecting updated expectations for the discount rate, profit margin and future P/E assumptions. Analyst Commentary The revised CA$2.25 price target signals that analysts are updating their view of Cresco Labs as they refresh discount rate, margin and P/E assumptions, rather than completely changing their stance on the business.
Narrative Update Apr 05

CL: Revised Outlook Will Support Future Upside From Speculative Buy Rating

Analysts have reduced their price target on Cresco Labs to CA$2.25 from CA$2.50, citing updated assumptions regarding fair value, discount rates, revenue growth, profit margins, and future P/E expectations. Analyst Commentary Analysts have adjusted their view on Cresco Labs by trimming the price target to CA$2.25 from CA$2.50 while maintaining a Speculative Buy stance, which reflects both perceived upside potential and meaningful execution risk.
Narrative Update Mar 22

CL: Lower P/E Assumptions Will Support A More Upside-Skewed Outlook

Analysts now see Cresco Labs' fair value as aligning with a trimmed CA$2.25 price target, down from CA$2.50. This reflects updated views on growth, margins and a lower future P/E assumption.
Narrative Update Mar 07

CL: Higher Future P/E Assumptions Will Shape A More Upside-Skewed Outlook

Analysts have lowered their price target on Cresco Labs to CA$2.25 from CA$2.50, reflecting updated views on revenue growth, profit margins, and a much higher assumed future P/E multiple. Analyst Commentary Bearish analysts are signaling a more cautious stance on Cresco Labs by trimming their price target to CA$2.25 from CA$2.50, even while still seeing speculative upside potential.
Narrative Update Feb 21

CL: Expanded Retail Footprint And Flexible Equity Program Will Support A More Optimistic Outlook

Analysts have revised their price target on Cresco Labs to CA$16.91 from CA$18.36, reflecting updated views on discount rates, revenue growth, profit margins, and future P/E assumptions. What's in the News Cresco Labs filed a follow on equity offering for up to CA$140 million of Subordinate Voting Shares through an at the market program, giving the company flexibility to raise capital over time (Key Developments).
Analysis Article Feb 12

Cresco Labs Inc. (CSE:CL) Shares Slammed 29% But Getting In Cheap Might Be Difficult Regardless

Cresco Labs Inc. ( CSE:CL ) shares have had a horrible month, losing 29% after a relatively good period beforehand. The...
Narrative Update Feb 06

CL: Expanded Retail And EU Entry Will Support A More Optimistic Outlook

Analysts have lifted their price target on Cresco Labs to US$1.94 from US$1.51, citing revised assumptions around revenue growth, profit margins, discount rate, and a lower future P/E multiple as key drivers of the change. What's in the News Cresco Labs filed a follow on equity offering of up to C$140 million in subordinate voting shares through an at the market program, adding flexibility to raise capital as needed (Key Developments).
Narrative Update Jan 23

CL: New German Entry Will Support Future Upside

Analysts have nudged their price target for Cresco Labs higher, now implying fair value of about $2.40 per share versus roughly $2.36 previously. The change reflects updated views on revenue growth, profit margins and future P/E assumptions.
Narrative Update Jan 09

CL: German Entry And Higher Margins Will Support Future Upside

Analysts have raised their price target for Cresco Labs from US$2.30 to about US$2.36, reflecting updated views on the company’s profit margin outlook and a lower assumed future P/E multiple. What's in the News Cresco Labs launched Cresco branded flower in Germany, marking its first commercial entry into the European Union and extending its growth plans beyond the U.S. cannabis market (Key Developments).
Narrative Update Dec 15

CL: Expanded Retail And European Entry Will Support Stronger Profitability

Analysts have modestly raised their price target on Cresco Labs to reflect an updated fair value estimate of approximately 2.30 dollars, up from about 2.16 dollars previously, citing expectations for stronger revenue growth, improved profit margins, a slightly lower discount rate, and a more reasonable future earnings multiple. What's in the News Entered the European Union with the launch of Cresco branded flower in Germany, using the market as a testbed for broader international expansion beyond U.S. cannabis (Key Developments).
Analysis Article Nov 26

Cresco Labs Inc. (CSE:CL) Not Doing Enough For Some Investors As Its Shares Slump 37%

Unfortunately for some shareholders, the Cresco Labs Inc. ( CSE:CL ) share price has dived 37% in the last thirty days...
Analysis Article Nov 08

Here's Why Cresco Labs (CSE:CL) Is Weighed Down By Its Debt Load

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Analysis Article Oct 12

Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 35% But Growth Is Lacking

Despite an already strong run, Cresco Labs Inc. ( CSE:CL ) shares have been powering on, with a gain of 35% in the last...
Analysis Article Sep 06

Is Cresco Labs Inc. (CSE:CL) Trading At A 49% Discount?

Key Insights Cresco Labs' estimated fair value is CA$3.23 based on 2 Stage Free Cash Flow to Equity Current share price...
Analysis Article Jul 31

Optimistic Investors Push Cresco Labs Inc. (CSE:CL) Shares Up 27% But Growth Is Lacking

Cresco Labs Inc. ( CSE:CL ) shareholders are no doubt pleased to see that the share price has bounced 27% in the last...
Analysis Article Jul 23

Cresco Labs (CSE:CL) Takes On Some Risk With Its Use Of Debt

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Analysis Article Jun 15

Cresco Labs Inc.'s (CSE:CL) 30% Share Price Plunge Could Signal Some Risk

The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 30...
Analysis Article May 01

Cresco Labs Inc.'s (CSE:CL) Shares Climb 31% But Its Business Is Yet to Catch Up

Cresco Labs Inc. ( CSE:CL ) shareholders would be excited to see that the share price has had a great month, posting a...
User avatar
New Narrative Mar 29

Expanding Production In Illinois, Pennsylvania And Kentucky Will Meet Demand

Expansion in Illinois and Pennsylvania and entry into Kentucky's market aim to boost revenue growth and market share.
Analysis Article Mar 07

Some Confidence Is Lacking In Cresco Labs Inc. (CSE:CL) As Shares Slide 27%

The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 27...
Analysis Article Jan 31

Is Cresco Labs (CSE:CL) A Risky Investment?

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...
Analysis Article Dec 14

Cresco Labs Inc. (CSE:CL) May Have Run Too Fast Too Soon With Recent 28% Price Plummet

To the annoyance of some shareholders, Cresco Labs Inc. ( CSE:CL ) shares are down a considerable 28% in the last...
Analysis Article Oct 24

Getting In Cheap On Cresco Labs Inc. (CSE:CL) Is Unlikely

It's not a stretch to say that Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.8x right now seems...
Analysis Article Aug 11

Cresco Labs Inc. (CSE:CL) Just Released Its Second-Quarter Results And Analysts Are Updating Their Estimates

Investors in Cresco Labs Inc. ( CSE:CL ) had a good week, as its shares rose 3.4% to close at CA$2.15 following the...
Analysis Article Jul 17

Are Investors Undervaluing Cresco Labs Inc. (CSE:CL) By 34%?

Key Insights Cresco Labs' estimated fair value is CA$3.60 based on 2 Stage Free Cash Flow to Equity Current share price...
Analysis Article Jun 19

Here's Why Cresco Labs (CSE:CL) Has A Meaningful Debt Burden

David Iben put it well when he said, 'Volatility is not a risk we care about. What we care about is avoiding the...
Analysis Article Jun 19

Cresco Labs Inc.'s (CSE:CL) 26% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

The Cresco Labs Inc. ( CSE:CL ) share price has fared very poorly over the last month, falling by a substantial 26...
Analysis Article Mar 16

Cresco Labs Inc. (CSE:CL) Released Earnings Last Week And Analysts Lifted Their Price Target To CA$5.41

The investors in Cresco Labs Inc. 's ( CSE:CL ) will be rubbing their hands together with glee today, after the share...
Analysis Article Mar 03

Investors Don't See Light At End Of Cresco Labs Inc.'s (CSE:CL) Tunnel And Push Stock Down 32%

Cresco Labs Inc. ( CSE:CL ) shareholders won't be pleased to see that the share price has had a very rough month...
Analysis Article Jan 26

Cresco Labs (CSE:CL) Seems To Be Using A Lot Of Debt

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Analysis Article Jan 04

Risks To Shareholder Returns Are Elevated At These Prices For Cresco Labs Inc. (CSE:CL)

There wouldn't be many who think Cresco Labs Inc.'s ( CSE:CL ) price-to-sales (or "P/S") ratio of 0.7x is worth a...

CEO Compensation Analysis

How has Charlie Bachtell's remuneration changed compared to Cresco Labs's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2026n/an/a

-US$134m

Dec 31 2025n/an/a

-US$135m

Sep 30 2025n/an/a

-US$52m

Jun 30 2025n/an/a

-US$46m

Mar 31 2025n/an/a

-US$84m

Dec 31 2024US$1mUS$492k

-US$74m

Sep 30 2024n/an/a

-US$67m

Jun 30 2024n/an/a

-US$172m

Mar 31 2024n/an/a

-US$155m

Dec 31 2023US$684kUS$450k

-US$176m

Sep 30 2023n/an/a

-US$339m

Jun 30 2023n/an/a

-US$234m

Mar 31 2023n/an/a

-US$211m

Dec 31 2022US$1mUS$450k

-US$212m

Sep 30 2022n/an/a

-US$65m

Jun 30 2022n/an/a

-US$326m

Mar 31 2022n/an/a

-US$318m

Dec 31 2021US$1mUS$450k

-US$320m

Sep 30 2021n/an/a

-US$360m

Jun 30 2021n/an/a

-US$73m

Mar 31 2021n/an/a

-US$105m

Dec 31 2020US$538kUS$450k

-US$102m

Sep 30 2020n/an/a

-US$76m

Jun 30 2020n/an/a

-US$98m

Mar 31 2020n/an/a

-US$64m

Dec 31 2019US$676kUS$350k

-US$43m

Compensation vs Market: Charlie's total compensation ($USD1.42M) is above average for companies of similar size in the Canadian market ($USD849.29K).

Compensation vs Earnings: Charlie's compensation has increased whilst the company is unprofitable.


CEO

Charlie Bachtell (46 yo)

11.3yrs
Tenure
US$1,419,586
Compensation

Mr. Charles Bachtell, also known as Charlie, is Director of Chicagoland Chamber of Commerce. Mr. Bachtell serves as Co-Founder and Chief Executive Officer at Cresco Labs Inc. (formerly known as Cresco Labs...


Leadership Team

NamePositionTenureCompensationOwnership
Charles Bachtell
Co-Founder11.3yrsUS$1.42m0.60%
CA$ 3.4m
Gregory Butler
President2.3yrsUS$806.98k0.012%
CA$ 69.6k
Robert Sampson
Co-Founder & Independent Directorno dataUS$76.60k1.12%
CA$ 6.4m
Sharon Schuler
Chief Financial Officer1.6yrsUS$141.67k0.019%
CA$ 108.8k
Ty Gent
Chief Operating Officer5.3yrsno datano data
Zach Marburger
Chief Information Officerno datano data0.081%
CA$ 463.2k
T.J. Cole
Senior Vice President of Corporate Development and Investor Relationsno datano datano data
John Schetz
General Counsel8yrsno data0.021%
CA$ 117.3k
Angie Demchenko
Chief People Officer6.9yrsno data0.066%
CA$ 379.0k
Joseph Ales
Senior VP of Operationsno datano datano data
Todd West
Executive Vice President of Operations8.4yrsno datano data
Drew Duval
Senior Vice President of Cultivation6.4yrsno datano data
6.7yrs
Average Tenure
48yo
Average Age

Experienced Management: CL's management team is seasoned and experienced (6.7 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Charles Bachtell
Co-Founder11.3yrsUS$1.42m0.60%
CA$ 3.4m
Robert Sampson
Co-Founder & Independent Director11.1yrsUS$76.60k1.12%
CA$ 6.4m
Marc Lustig
Independent Director6.4yrsUS$68.34k9.94%
CA$ 56.9m
Gerald Corcoran
Independent Director9.3yrsUS$89.38k0.34%
CA$ 1.9m
Thomas J. Manning
Chairman of the Board9.7yrsUS$135.00k0.063%
CA$ 361.7k
Michele Roberts
Independent Director6yrsUS$128.00k0.0054%
CA$ 31.0k
Randy Podolsky
Independent Director9.5yrsUS$83.75k0.082%
CA$ 470.0k
9.5yrs
Average Tenure
68yo
Average Age

Experienced Board: CL's board of directors are considered experienced (9.5 years average tenure).


Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/03 13:09
End of Day Share Price 2026/06/03 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cresco Labs Inc. is covered by 13 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Aaron GreyAlliance Global Partners
Frederico Yokota Choucair GomesATB Cormark
Russell StanleyBeacon Securities Limited